imatinib mesylate has been researched along with Rhabdoid Tumor in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frühwald, MC; Hasselblatt, M; Jeibmann, A; Koos, B; Leuschner, I; Lünenbürger, H; Mertsch, S; Nupponen, NN; Paulus, W; Roselli, A | 1 |
1 other study(ies) available for imatinib mesylate and Rhabdoid Tumor
| Article | Year |
|---|---|
The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors.
Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Kidney Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rhabdoid Tumor | 2010 |